Other Names for this Disease
- Heparin-induced thrombocytopenia
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
heparin resulting in an abnormally low amount of platelets (thrombocytopenia). HIT is usually an immune response which typically occurs 4-10 days after exposure to heparin; it can lead to serious complications and be life-threatening. This condition occurs in up to 5% of those who are exposed to heparin. Characteristic signs of HIT are a drop in platelet count of greater than 50% and/or the formation of new blood clots during heparin therapy. The first step of treatment is to discontinue and avoid all heparin products immediately. Often, affected individuals require another medicine to prevent blood clotting (anticoagulants). Heparin-induced thrombocytopenia (HIT) is an adverse reaction to the drug
Last updated: 5/3/2012
- Greinacher A & Lubenow N. Heparin-induced thrombocytopenia. Orphanet. 2003; http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=3325. Accessed 5/3/2012.
- Heparin-induced thrombocytopenia. Medscape Reference. 2011; http://emedicine.medscape.com/article/1357846-overview. Accessed 5/3/2012.
- The National Heart, Lung, and Blood Institute (NHLBI) provides leadership for a national program in diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Since October 1997, the NHLBI has also had administrative responsibility for the NIH Woman's Health Initiative. Click on the link to view information on this topic.
- Medscape Reference provides information on this topic. You may need to register to view the medical textbook, but registration is free.
- Orphanet is a European reference portal for information on rare diseases and orphan drugs. Access to this database is free of charge.
- PubMed is a searchable database of medical literature and lists journal articles that discuss Heparin-induced thrombocytopenia. Click on the link to view a sample search on this topic.